Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.
[0089] Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.
The present invention relates to an isolated mammalian cell population wherein: - at least about 90% of the cells of the population express THY1, CD99 and CD63; - about 10% or less of the cells of the population express CD34 and PTPRC.
The present invention relates to a gingival fibroblast-derived product for use in the treatment or prevention of an immune-related disease in an individual.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
The present invention relates to a gingival fibroblast-derived product for use in the treatment or prevention of an immune-related disease in an individual.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61P 37/00 - Drugs for immunological or allergic disorders
The present invention relates to a gingival fibroblast-derived product and its use in methods for the prevention or treatment of orthopedic pathologies in an individual.
The present invention relates to a product derived from gingival fibroblast, to be used in the prevention or treatment of orthopedic pathologies in a person.
The present invention relates to a balloon catheter device (1) intended to be placed within a conduit (2) of a biological flux, for administering a therapeutic composition to luminal walls (3) of said conduit (2), comprising: - an outer catheter (4) and a distal balloon (8) and a proximal balloon (9) around the outer catheter (4), wherein a first segment (10) of the wall of the outer catheter between the distal balloon (8) and the proximal balloon (9) is permeable to the therapeutic composition, a second segment (11) of the wall of the outer catheter between the proximal balloon (9) and the proximal end is permeable to the biological flux; - a hollow cylinder (13) having a wall (14) substantially impermeable to the biological flux, with a first opened end (15) and a second opened end (16), wherein the first opened end (15) is hermetically fitted through the opening (7) of the distal end of the outer catheter, and the second opened end (16) opens in the portion of the lumen of the outer catheter underneath said second segment (11); - at least two inner catheters for respectively inflating the distal and proximal balloons (17,18) and at least one inner catheter for delivering the therapeutic composition (19).
The present invention relates to a method for the cosmetic prevention or treatment of skin ageing in an individual, comprising administering to said individual a cosmetically active quantity of a gingival fibroblast-derived product.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
patents
